FrancophonIA/ELRC3.0 huggingface dataset:
English: The study included 1,803 women previously treated with surgery who received Zometa every six months for three years, and were followed up for five years.
Slovenian: V študiji so sodelovale 1 803 ženske, ki so bile predhodno operirane in so tri leta vsakih šest mesecev prejemale zdravilo Zometa, nato pa so jih spremljali še nadaljnjih pet let.
English: It is approved for use as a drip into a vein every three to four weeks to prevent bone complications such as fractures in adults with advanced cancer that is affecting the bone.
Slovenian: Odobreno je za uporabo kot kapalna infuzija v veno vsake tri do štiri tedne za preprečevanje z okostjem povezanih težav, kot so zlomi pri odraslih z napredovalim rakom, ki zajamejo kosti.
English: All women also received goserelin, a medicine that suppresses the activity of the ovaries.
Slovenian: Vse ženske so prejele tudi goserelin, zdravilo, ki zavira delovanje jajčnikov.
English: The study measured ‘disease-free survival' (how long the patients lived without cancer).
Slovenian: V študiji so merili „preživetje brez ponovitve bolezni“ (kako dolgo so bolnice živele brez raka).
English: It also had concerns regarding the way the study in early breast cancer had been carried out.
Slovenian: Prav tako je izrazil zadržke glede načina izvedbe študije pri zgodnjem raku dojke.
English: The study compared anastrozole and tamoxifen (medicines used in hormone-receptor positive breast cancer) with or without Zometa.
Slovenian: V študiji so primerjali anastrozol in tamoksifen (zdravili, ki se uporabljata pri zdravljenju raka dojke s pozitivnimi hormonski receptorji) z zdravilom Zometa ali brez njega.
English: On 14 December 2010, Novartis Europharm Limited officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a new indication for Zometa, in the treatment of early breast cancer in premenopausal women.
Slovenian: Družba Novartis Europharm Limited je dne 14. decembra 2010 uradno obvestila Odbor za zdravila za uporabo v humani medicini (CHMP), da želi umakniti vlogo za novo indikacijo pri zdravilu Zometa za zdravljenje zgodnjega raka dojke pri ženskah pred menopavzo.
English: Zometa is a medicine that contains the active substance zoledronic acid.
Slovenian: Zometa je zdravilo, ki vsebuje zdravilno učinkovino zoledronsko kislino.
English: Zometa was only to be used if the breast cancer was ‘hormone receptor positive' (the cancer is likely to respond to hormonal treatment), and in combination with hormonal treatment.
Slovenian: Zdravilo Zometa naj bi se uporabljalo le, kadar ima rak „hormonsko pozitivne receptorje“ (rak se bo verjetno odzval na hormonsko zdravljenje), in v kombinaciji s hormonskim zdravljenjem.
English: Zoledronic acid, the active substance in Zometa, blocks an enzyme called ‘farnesyl pyrophosphate synthase'.
Slovenian: Zdravilna učinkovina v zdravilu Zometa, zoledronska kislina, zavira encim „farnezil pirofosfat-sintaza“.
English: By blocking this enzyme, it was expected to prevent the growth of cancer cells and cause their death.
Slovenian: Z zaviranjem tega encima naj bi preprečevala rast rakavih celic in povzročila njihovo uničenje.
English: Early breast cancer is breast cancer that has not spread and has been treated by surgery.
Slovenian: Zgodnji rak dojke je rak dojke, ki se še ni razširil in je bil operiran.
English: The company provided data from one main study to support the use of Zometa in early breast cancer.
Slovenian: Družba je predložila podatke iz ene glavne študije v podporo uporabi zdravila Zometa pri zgodnjem raku dojke.
English: The Committee noted that the treatments used in the control groups to which Zometa was compared were not all representative of the standards of care in Europe.
Slovenian: Odbor je menil, da vsa zdravljenja v kontrolnih skupinah, s katerimi so primerjali zdravljenje z zdravilom Zometa, niso bila povsem v skladu s standardno oskrbo v Evropi.
English: The company informed the CHMP that this withdrawal does not an impact on ongoing clinical trials with Zometa.
Slovenian: Družba je CHMP obvestila, da umik nima nobenih posledic za klinična preskušanja z zdravilom Zometa, ki trenutno potekajo.
English: Therefore, at the time of the withdrawal, the CHMP was of the opinion that the medicine could not have been approved based on the data presented by the company.
Slovenian: Tako je CHMP v času umika menil, da na podlagi predloženih podatkov družbe zdravila ni mogoče odobriti.
English: Based on the review of the data and the company's responses to the CHMP list of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Zometa could not have been approved for the adjuvant treatment of early breast cancer.
Slovenian: Na podlagi pregleda podatkov in odgovorov družbe na seznam vprašanj, ki jih je zastavil CHMP, je imel Odbor v času umika vloge zadržke in je začasno menil, da zdravila Zometa ni mogoče odobriti za dodatno zdravljenje zgodnjega raka dojke.
English: Zometa was expected to be used as an adjuvant (add-on) in the treatment of early breast cancer in women who have not been through the menopause.
Slovenian: Zdravilo Zometa naj bi se uporabljalo kot adjuvans (dodatno zdravilo) pri zdravljenju zgodnjega raka dojke pri ženskah, ki še niso bile v menopavzi.
English: Zometa can also be used to treat hypercalcaemia (high levels of calcium in the blood) caused by tumours.
Slovenian: Zdravilo Zometa se lahko uporablja tudi za zdravljenje tumorsko povzročene hiperkalciemije (visokih ravni kalcija v krvi).
English: There are no consequences on the use of Zometa in its authorised indications.
Slovenian: Pri uporabi zdravila Zometa za odobrene indikacije ni nobenih posledic.
English: The way Zometa is expected to works in early breast cancer is not fully elucidated.
Slovenian: Natančen način delovanja zdravila Zometa pri zgodnjem raku dojke še ni povsem pojasnjen.
English: What is happening with Zometa for the prevention of bone events in cancer patients?
Slovenian: Kakšne so posledice za zdravilo Zometa, indicirano za preprečevanje z okostjem povezanih težav pri bolnikih z rakom?
English: The CHMP was assessing the company's responses to the questions at the time of the withdrawal.
Slovenian: V času umika je CHMP ocenjeval odgovore družbe na podana vprašanja.
English: The Committee had concerns that the anti-tumour activity of Zometa when used as add-on had not been sufficiently supported by the data from the study.
Slovenian: Odbor je imel zadržke, da podatki iz študije niso ustrezno potrdili protitumorskega delovanja zdravila Zometa, kadar se uporablja kot dodatek.
English: Studies and Reviews
Slovenian: Študije in pregledi
English: Particular attention should be given to indication, dosage and duration of treatment.
Slovenian: Posebno pozornost je treba nameniti indikaciji, odmerjanju in trajanju zdravljenja.
English: Post-marketing surveillance
Slovenian: Postmarketinško spremljanje
English: Further updates of the Risk Management Plan should be submitted for assessment at national level.
Slovenian: Nadaljnje posodobitve načrta za obvladovanje tveganja je treba predložiti v oceno na nacionalni ravni.
English: The communication shall include comprehensive information on the safety risks associated with the use of nimesulide.
Slovenian: Obveščanje mora vključevati izčrpne informacije o varnostnih tveganjih, povezanih z uporabo nimesulida.
English: The protocol should be submitted to the CHMP by 3 months after the completion of the final study report of the retrospective study for review and agreement.
Slovenian: Protokol je treba v 3 mesecih po zaključku končnega poročila o retrospektivni študiji predložiti v pregled in soglasje CHMP .
English: A report should be provided to the National Competent authorities for assessment every 6 months as part of the PSUR (starting within one semester after adoption of the Commission Decision).
Slovenian: Poročilo je treba vsakih 6 mesecev predložiti v oceno pristojnim nacionalnim organom kot del rednega poročila o varnosti zdravila (z začetkom v 6 mesecih po sprejetju odločbe Komisije).
English: This retrospective study should lead to a follow-up prospective study in transplant centres.
Slovenian: Tej retrospektivni študiji mora slediti prospektivna spremljevalna študija v centrih za presajanje organov.
English: The final study reports of the above studies should be submitted to the National Competent Authorities for assessment.
Slovenian: Končno poročilo zgornjih študij je treba predložiti v oceno pristojnim nacionalnim organom.
English: The draft DHPC should be submitted to the CHMP within one month after adoption of the Commission Decision.
Slovenian: Osnutek dopisa „Spoštovani zdravnik“ je treba v enem mesecu po sprejetju odločbe Komisije predložiti CHMP.
English: The MAHs should strengthen the medical review, refine the monitoring of reporting rates, and improve the quality of Individual Case Safety Reports of nimesulide.
Slovenian: Imetniki dovoljenja za promet z zdravilom morajo okrepiti medicinske preglede, zagotoviti natančnejše spremljanje števila opaženih primerov in izboljšati kakovost varnostnih poročil o posameznih primerih za nimesulid.
English: • The MAHs should conduct a pre-clinical study on identification of reactive metabolites and protein adduct information.
Slovenian: • Imetniki dovoljenja za promet z zdravilom morajo izvesti predklinično študijo za pridobitev informacij o reaktivnih metabolitih in proteinskih aduktih.
English: This study should address the relative risk of nimesulide in respect to other NSAIDs to cause severe hepatic reactions leading to transplants.
Slovenian: Študija mora obravnavati relativno tveganje nimesulida za povzročitev hudih jetrnih reakcij, ki zahtevajo presaditev, v primerjavi z drugimi nesteroidnimi protivnetnimi zdravili.
English: Hepatic reactions should be given cumulatively and for the period covered by the PSUR.
Slovenian: Jetrne reakcije morajo biti podane kumulativno in za obdobje, ki ga obravnava redno poročilo o varnosti zdravila.
English: • The MAHs should conduct a retrospective cohort study in transplant centres.
Slovenian: • Imetniki dovoljenja za promet z zdravilom morajo izvesti retrospektivno kohortno študijo v centrih za presajanje organov.
English: Competent authorities for assessment within one year after adoption of the Commission Decision.
Slovenian: Poročilo je treba v enem letu po sprejetju odločbe Komisije predložiti v oceno pristojnim nacionalnim organom.
English: • The MAHs should inform healthcare professionals on the outcome of this review on nimesulide via a “Direct Healthcare Professional Communication” (DHPC) to be agreed with the CHMP.
Slovenian: • Imetniki dovoljenja za promet z zdravilom morajo obvestiti zdravstvene delavce o rezultatih tega pregleda za nimesulid z dopisom „Spoštovani zdravnik“, za katerega mora dati soglasje CHMP.
English: These PSURs should include a specific overview of the hepatic reactions.
Slovenian: Ta redna poročila o varnosti zdravila morajo vključevati poseben pregled jetrnih reakcij.
English: • The MAHs should conduct a review of epidemiological data to review the risk of hepatic damage from nimesulide in comparison with other NSAIDs
Slovenian: • Imetniki dovoljenja za promet z zdravilom morajo izvesti pregled epidemioloških podatkov, da bi ugotovil, kakšno je tveganje za jetrne poškodbe zaradi nimesulida v primerjavi z drugimi nesteroidnimi protivnetnimi zdravili.
English: • The MAHs should submit a revised Risk Management Plan for nimesulide, considering the comments raised during this procedure, to the CHMP.
Slovenian: • Imetniki dovoljenja za promet z zdravilom morajo CHMP predložiti pregledan načrt o obvladovanju tveganja, povezanega z nimesulidom, ter pri tem upoštevati pripombe, ki so nastale med tem postopkom.
English: The MAHs should expedite and submit all safety reports and case series in PSURs for nimesulide, with a six monthly periodicity.
Slovenian: Imetniki dovoljenja za promet z zdravilom morajo vsakih šest mesecev pripraviti in predložiti vsa varnostna poročila in serije primerov za nimesulid v rednih poročilih o varnosti zdravila.
English: These PSURs should be submitted to the National Competent Authorities for assessment.
Slovenian: Poročila o varnosti zdravila morajo biti predložena v oceno pristojnim nacionalnim organom.
English: The following conditions in relation to post-marketing surveillance, studies and review and communication shall be fulfilled by the Marketing Authorisation Holders of nimesulide containing medicinal products (systemic formulation).
Slovenian: Imetniki dovoljenja za promet z zdravili, ki vsebujejo nimesulid (sistemska uporaba), morajo izpolnjevati naslednje pogoje v zvezi s postmarketinškim spremljanjem, študijami in pregledi ter obveščanjem.
English: • The MAHs should perform a survey to clarify the modes of use of nimesulide in selected EU Member States to identify potential misuse.
Slovenian: • Za ugotovitev možnih zlorab morajo imetniki dovoljenja za promet z zdravilom izvesti raziskavo, s katero se pojasnijo načini uporabe nimesulida v določenih državah članicah EU.
English: • The MAHs should perform a monitoring activity to evaluate the effectiveness of risk communication on nimesulide.
Slovenian: • Za oceno učinkovitosti obveščanja o tveganju, povezanim z nimesulidom, morajo imetniki dovoljenja za promet z zdravilom opravljati dejavnosti spremljanja.
English: Name Strength
Slovenian: Izmišlje no ime
English: Package size
Slovenian: Velikost pakiranja intravenska
English: Medicinal product no longer authorised
Slovenian: Zdravilo nim a veā dovoljenja za prom et
English: ETHYPHARM 17/21 rue Saint-Matthieu 78550 Houdan
Slovenian: ETHYPHARM 17/21 rue SaintMatthieu 78550 Houdan
English: 1 ml (120 mg/ml) 1 pre-filled pen + 2 alcohol pads
Slovenian: 1 ml (120 mg/ml) 1 napolnjen injekcijski peresnik + 2 alkoholnima zložencema
English: 75014 PARIS
Slovenian: 75014 Paris France
English: em., H-1036 Budapest Hungary
Slovenian: H-1036 Budapest Hungary
English: 92931 PARIS LA DEFENSE FRANCE
Slovenian: 92931 Paris la Defence France
English: 28108 Alcobendas (Madrid) Spain
Slovenian: 28108 Alcobendas Madrid
English: Rua Quinta Pinheiro, 5, Outurela - Carnaxide
Slovenian: Rua Quinta Pinheiro, 5, Outurela
English: LADEEPHARMA PHARMACEUTICAL Limited Lajos u. 48-66, E ép.
Slovenian: Ladeepharma Pharmaceutical Limited Lajos u. 48-66
English: MAROUSSI GR-15125 ATHENS
Slovenian: Athens GR-15125 Greece
English: Comprimidos
Slovenian: tableta
English: Osa Mayor, 4 28023 Aravaca (Madrid) Spain
Slovenian: Osa Mayor, 4 28023 Aravaca Madrid
English: Ilford, Essex IG3 8BS
Slovenian: Essex IG3 8BS
English: TEVA PHARMA, SLU Anabel Segura 11, Edificio Albatros B, 1ª planta 28108 Alcobendas (Madrid) Spain
Slovenian: Teva Pharma, SLU Anabel Segura 11 Edificio Albatros B 1ª planta 28108 Alcobendas Madrid
English: Sandoz d.d Verovskova 57, 1000 Ljubljana
Slovenian: Sandoz d.d Verovskova 57 1000 Ljubljana Slovenia
English: LABORATOIRES MAJORELLE 80-82 rue Gallieni 92100 BOULOGNE BILLANCOURT FRANCE
Slovenian: Laboratoires Majorelle 80-82 rue Gallieni 92100 Boulogne Billancourt
English: List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, marketing authorisation holders in the member states for cyproterone acetate/ethinylestradiol containing medicinal products
Slovenian: Priloga I Seznam imen, farmacevtskih oblik, jakosti zdravil, poti uporabe in imetnikov dovoljenja za promet z zdravilom v državah članicah
English: Berlifarma - Especialidades Farmaceuticas, Lda.
Slovenian: BerlifarmaEspecialidades Farmaceuticas, Lda.
English: United Kingdom Fannin (UK) Limited, 42-46 Booth Drive, Park Farm
Slovenian: Velika Britanija Fannin (UK) Limited 42-46 Booth Drive
English: United Kingdom Generics (UK) Limited, Station Close, Potters Bar, Hertfordshire EN6 1TL
Slovenian: Generics (UK) Limited Station Close Potters Bar Hertfordshire EN6 1TL United Kingdom
English: Bayer S.p.A. Viale Certosa, 130 - 20156 Milano (MI) Italy
Slovenian: Viale Certosa, 130 20156 Milano (MI) Italy
English: Parc d'Activités des Peupliers - 25 rue des Peupliers 92000 NANTERRE FRANCE
Slovenian: 25 rue des Peupliers 92000 Nanterre France
English: EG LABO - LABORATOIRES EUROGENERICS 12 rue Danjou le Quintet bâtiment A 92517 BOULOGNE BILLANCOURT CEDEX FRANCE
Slovenian: LABORATOIRES EUROGENERICS 12 rue Danjou le Quintet bâtiment A 92517 Boulogne Billancourt Cedex France
English: CYPROTERONE/ETHIN YLESTRADIOL BAYER 35 µg
Slovenian: CYPROTERONE/ETHINYLESTRADIOL BAYER 35 µg
English: 220, avenue de la Recherche 59120 Loos
Slovenian: Bayer Santé 220, avenue de la Recherche 59120 Loos France
English: 3 DDD Pharma N.V. Diestersteenweg 349 3510 Hasselt Belgium
Slovenian: Diestersteenweg 349 3510 Hasselt Belgium
English: Medico Uno Worldwide Ltd.,2 Grigori Afxentiou Street + Larnaca 6023
Slovenian: 2 Grigori Afxentiou Street Larnaca 6023
English: United Kingdom Teva UK Limited, Brampton Road, Hampden Park,
Slovenian: Velika Britanija Teva UK Limited Brampton Road
English: EFFIK bâtiment ''le Newton'' 9-11 rue Jeanne Braconnier 92366 MEUDON LA FORET FRANCE
Slovenian: EFFIK bâtiment ''le Newton'' 9-11 rue Jeanne Braconnier
English: United Kingdom Strandhaven Limited, 600 High Road, Seven Kings,
Slovenian: Velika Britanija Strandhaven Limited 600 High Road
English: 49 avenue Georges Pompidou 92593 LEVALLOIS PERRET CEDEX
Slovenian: 92593 Levallois Perret Cedex
English: United Kingdom Stragen UK Limited, Castle Court, 41 London Road,
Slovenian: Velika Britanija Stragen UK Limited Castle Court 41
English: United Kingdom Bayer plc, Bayer House, strawberry Hill, Newbury, Berkshire RG14 1JA
Slovenian: Strawberry Hill Newbury, Berkshire RG14 1JA,
English: United Kingdom Farmalider SA, Calle Aragoneses 15, Alcobendas, Madrid E-28108
Slovenian: Farmalider S.A. Calle Aragoneses, 15 28108 Alcobendas Madrid
English: United Kingdom Chatfiled Pharmaceuticals Limited, Kramer Mews,
Slovenian: Velika Britanija Chatfield Pharmaceuticals Limited
English: Marszałka J.Piłsudskiego 5 95-200 Pabianice Poland
Slovenian: 95-200 Pabianice Poland
English: Poland acis Arzneimittel GmbH Lil-Dagover-Ring 7 82031 Grunwald Germany
Slovenian: Acis Arzneimittel GmbH Lil-Dagover-Ring 7 82031 Grünwald Germany
English: Diane 2000 micrograms/35 micrograms filmcoated tablets
Slovenian: Diane 2000 micrograms/35 micrograms film-coated tablets
English: Mithra Pharmaceuticals S.A. Rue Saint Georges 5 4000 Liège
Slovenian: Rue Saint Georges 5 4000 Liège
English: Reigate, Surrey RH2 9RJ
Slovenian: Reigate, Surrey RH2 PRJ United Kingdom
English: Estonia ratiopharm GmbH Graf-Arco-Strasse 3 D-89079 Ulm Germany
Slovenian: Ratiopharm GmbH Graf-Arco-Strasse 3 DE-89079 Ulm Germany
English: BAYER ΕΛΛΑΣ ΑΒΕΕ SOROU 18-20
Slovenian: Bayer Hellas ABEE Sorou 18-20
English: South, Wellingborough, Kent NN8 6GT
Slovenian: Kent NN8 6GT
English: United Kingdom Sandoz Limited, Frimley Business Park, Frimley,
Slovenian: Velika Britanija Sandoz Limited Frimley Business Park Frimley, Camberley Surrey GU16 7SR United Kingdom
English: Castle Court 41, London Road, Reigate, Surrey RH2 PRJ,
Slovenian: London Road Reigate, Surrey RH2 PRJ United Kingdom
English: Fannin UK CoCyprindiol 2000/35 Tablets
Slovenian: Fannin UK Co-Cyprindiol 2000/35 Tablets
English: Chloe 35 micrograms/2 mg film-coated tablets
Slovenian: Chloe 35 micrograms/2 mg filmobložena tabletas
English: PIERRE FABRE DERMATOLOGIE 45 place Abel Gance 92100 BOULOGNE FRANCE
Slovenian: Luksemburg Pierre Fabre Dermatologie 45, place Abel Gance
English: Stragen UK Ltd.
Slovenian: Medico Uno Worldwide Ltd.
English: Patient Health Protection
Slovenian: Imetnik dovoljenja za promet z zdravilom
English: Bellgyn "ratiopharm" 2 mg/ 0,035 mgüberzogene Tabletten
Slovenian: Bellgyn "ratiopharm" 2 mg/ 0,035 mg - überzogene Tabletten
English: 11-15 quai de Dion Bouton 92800 PUTEAUX FRANCE
Slovenian: 92800 Puteaux France
English: Almirall Hermal GmbH Scholzstr.
Slovenian: Taurus Pharma GmbH Benzstr.
English: ACETATO DE CIPROTERONA/ETINIL ESTRADIOL SANDOZ 2 mg/0,035 mg comprimidos recubiertos EFG
Slovenian: CIPROTERONA/ETINILESTRADIOL SANDOZ 2 mg/0,035 mg comprimidos recubiertos EFG
English: 21465 Reinbek Germany
Slovenian: 61352 Bad Homburg Germany
English: U kabelovny 130 Dolní Měcholupy 102 37, Praha 10 Czech Republic
Slovenian: U kabelovny 130 102 37 Praha 10 Dolní Měcholupy Cezch Republic
English: Jan Emiel Mommaertslaan 14 1831 Machelen Belgium
Slovenian: B-1831 Machelen Belgium
English: Cyproteronacetaat/Eth inylestradiol Sandoz 2/0,035, omhulde tabletten
Slovenian: Cyproteronacetaat/Ethinylestradiol Sandoz 2/0,035, omhulde tabletten
English: BN22 9AG
Slovenian: East Sussex BN22 9AG United Kingdom
English: Cyproteronacetaat/eth inylestradiol Actavis 2/0,035 mg, filmomhulde tabletten 2 mg/0,035 mg
Slovenian: Cyproteronacetaat/ethinylestradiol Actavis 2/0,035 mg, filmomhulde tabletten 2 mg/0,035 mg
English: TEVASANTE
Slovenian: Alcobendas
English: Alternova A/S, Lodshusvej 11, DK-4230 Skælskør Denmark
Slovenian: DK-4230 Skælskør Denmark
English: FIDIA Farmaceutici S.p.A., Via Ponte della Fabbrica, 3/A, 35031 Abano Terme (PD) Italy
Slovenian: 35031 Abano Terme (PD) Italy
English: Strandhaven CoCyprindiol 2000/35 Tablets
Slovenian: Strandhaven Co-Cyprindiol 2000/35 Tablets
English: Acetato Ciproterona/ Etinilestradiol 2 mg/ 0,035 mg
Slovenian: Acetato Ciproterona/ Etinilestradiol 2 mg/ 0,035 mg Comprimidos
English: Sandoz A/S, Edvard Thomsens Vej 14, DK-2300 København S
Slovenian: Edvard Thomsens Vej 14 DK-2300 København S Denmark
English: 0,035mg/2mg überzogene Tablette
Slovenian: Diane-35 0,035 mg/2mg überzogene Tablette
English: Cyproteronacetaat/Eth inylestradiol 2/0,035 PCH, omhulde tabletten 2 mg/0,035 mg
Slovenian: Cyproteronacetaat/Ethinylestradiol 2/0,035 PCH, omhulde tabletten 2 mg/0,035 mg
English: Clevia 2 mg/0,035 mg Filmtabletten
Slovenian: Cyprotomin 2 mg/0,035 mg Filmtabletten
English: CYPROTERONE/ETHIN YLESTRADIOL DCI PHARMA 2 mg/0,035 mg
Slovenian: CYPROTERONE/ETHINYLESTRADIOL DCI PHARMA 2 mg/0,035 mg
English: CYPROTERONE/ETHIN YLESTRADIOL RATIOPHARM 2 mg/0,035 mg
Slovenian: CYPROTERONE/ETHINYLESTRADIOL RATIOPHARM 2 mg/0,035 mg
English: Generics (UK) Limited trading as Mylan
Slovenian: Velika Britanija Generics (UK) Limited Station Close
English: Orifarm Generics Energivej 15 - POB 69 DK-5260 Odense S Denmark
Slovenian: DK-5260 Odense S. Denmark
English: CYPROTERONE/ETHIN YLESTRADIOL RANBAXY 2 mg/0,035 mg
Slovenian: CYPROTERONE/ETHINYLESTRADIOL RANBAXY 2 mg/0,035 mg
English: Cyproteronacetaat/eth inylestradiol Apotex 2/0,035 mg, omhulde tabletten
Slovenian: Cyproteronacetaat/ethinylestradiol Apotex 2/0,035 mg, omhulde tabletten
English: FARMALIDER, S.A.
Slovenian: Generis Farmaceutica, S.A.
English: Camilette CoCyprindiol 2000/35 Tablets
Slovenian: Camilette Co-Cyprindiol 2000/35 Tablets tableta
English: Cyproteronacetaat/Eth inylestradiol CF 2/0,035 mg, omhulde tablet
Slovenian: Cyproteronacetaat/Ethinylestradiol CF 2/0,035 mg, omhulde tablet
English: CYPROTERONE/ETHIN YLESTRADIOL SANDOZ 2 mg/0,035 mg
Slovenian: CYPROTERONE/ETHINYLESTRADIOL SANDOZ 2 mg/0,035 mg
English: Cyproteronacetaat/eth inylestradiol ratiopharm 2 mg/0,035 mg, omhulde tabletten
Slovenian: Cyproteronacetaat/ethinylestradiol ratiopharm 2 mg/0,035 mg, omhulde tabletten
English: CYPROTERONE/ETHIN YLESTRADIOL ZENTIVA 2 mg/0,035 mg
Slovenian: CYPROTERONE/ETHINYLESTRADIOL ZENTIVA 2 mg/0,035 mg
English: Cyproteronacetaat/Eth inylestradiol Mylan 2 mg/0,035 mg, omhulde tabletten
Slovenian: Cyproteronacetaat/Ethinylestradiol Mylan 2 mg/0,035 mg, omhulde tabletten
English: CYPROTERONE/ETHIN YLESTRADIOL TEVA 2 mg/0,035 mg
Slovenian: CYPROTERONE/ETHINYLESTRADIOL TEVA 2 mg/0,035 mg
English: CYPROTERONE/ETHIN YLESTRADIOL ZYDUS 2 mg/0,035 mg
Slovenian: CYPROTERONE/ETHINYLESTRADIOL ZYDUS 2 mg/0,035 mg
English: CYPROTERONE/ETHIN YLESTRADIOL EG 2 mg/0,035 mg
Slovenian: CYPROTERONE/ETHINYLESTRADIOL EG 2 mg/0,035 mg
English: Aragoneses, 15
Slovenian: Piłsudskiego 5
English: GINESERVICE 0,035 mg/2 mg comprimidos EFG
Slovenian: ETINILESTRADIOL/CIPROTERONA GINESERVICE 0,035 mg/2 mg comprimidos EFG
English: HEATON a.s. Na Pankráci 14 Praha 4
Slovenian: Na Pankráci 332/14 14000 Praha 4
English: Orifarm Generics A/S, Postbox 69, Energivej 15, DK-5260 Odense S., Denmark
Slovenian: Orifarm Generics A/S Postbox 69